2 results
Approved WMOCompleted
To compare the effect of semaglutide 1.0 mg once-weekly versus exenatide extended release (ER) 2.0 mg once-weekly on glycaemic control after 56 weeks of treatment.
Approved WMOPending
Primary objective:- To evaluate the anti-tumor efficacy of HLX10 in combination with chemotherapy and concurrent radiotherapy in subjects with LS-SCLCSecondary objectives:- To evaluate the safety of HLX10 in combination with chemotherapy and…